Project Grant R41AI192061
Award Date
5/9/25
Completion Date
4/30/27
Dollars Obligated
$307K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the GATA2-TGF-beta-TAL1 pathway as a critical mediator of natural killer (NK) cell development. The $729,047 award, effective from December 27, 2024 to November 30, 2029, will allow researchers at the Medical College of Wisconsin, Inc. to employ advanced techniques such as...
This $797,711 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of an in vivo T-cell therapy to treat HIV. The primary goal is to transform T-cells in the patient's body to express receptors capable of recognizing and killing HIV-infected cells, without the risks associated with ex vivo cell extraction and chromosomal transformation. The approach involves...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $343,744 to develop a comprehensive product development strategy for an Investigational New Drug (IND) submission. The goal is to facilitate Phase I clinical trials of a novel gene therapy approach using chimeric antigen receptor (CAR)-modified hematopoietic stem/progenitor cells to functionally cure HIV infection. The...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop engineered mesenchymal stromal cells (MSCs) with enhanced immunosuppressive properties for the treatment of graft-versus-host disease (GVHD) and inflammatory bowel disease (IBD). The $3,089,194 award, granted on July 11, 2024, will enable the Mayo Clinic, a renowned non-profit academic medical...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $561,030 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Research Institute to develop a novel cell therapy for preventing and treating viral infections in immunocompromised patients following hematopoietic stem cell transplantation. The project aims to enhance the efficacy of virus-specific T cell therapies by genetically modifying the cells to be resistant to alemtuzumab, an...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,921 to Ubiquitx Inc., a New York-based biotechnology company, to develop and evaluate a Chimeric Ligands for Induced Proximity (CLIPS) platform. The goal is to upregulate the presentation of disease-associated peptide antigens on major histocompatibility complex (MHC) class I molecules, enhancing the immune...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $200,016 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) to develop a non-viral platform for genome editing of hematopoietic stem cells to treat Artemis-deficient severe combined immunodeficiency (ART-SCID). The 5-year grant, effective May 8, 2025 through April 30, 2030, will support Dr. Matthew Kan's research to...
This $160,518 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to establish the safety and preliminary efficacy of adoptive immunotherapy with donor-derived SARS-CoV-2-specific T cells (CSTs) for prophylaxis against SARS-CoV-2 infection in patients post-hematopoietic stem cell transplant (HSCT). The award provides funding to conduct an FDA- and IRB-approved Phase I clinical trial (NCT 05141058) and to develop CSTs...
This $104,435 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research supports research conducted by Dr. Sonali Bracken at Duke University. The objective is to delineate immune pathways that contribute to lung fibrosis in patients with chronic graft-versus-host disease (cGVHD), a leading cause of morbidity and mortality after hematopoietic stem cell transplantation. The research will investigate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $307,091 to Aleutian Therapeutics, Inc. to develop immune evasive strategies for allogeneic cell replacement therapies. The research aims to determine the minimal number of genetic edits required to enable human pluripotent stem cell-derived therapies to overcome xenogeneic immune rejection without the need for...